A Phase 3 interventional study of Dulaglutide and Semagludtide in Non-diabetec Obesity and Obesity (Disorder), sponsored by Zagazig University. Completed at 1 site in Saudi Arabia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Zagazig University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 143 studies testing semaglutide in Obesity, this one is the 51st largest by enrollment, is one of 23 that started in 2025, is one of 42 in phase 3, and was the 130th registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 24 · Phase 3 46 · Phase 4 40
First in 2014; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 100 across the 143 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 143 have an industry lead sponsor. The 10 most frequent:
Zagazig University is the lead sponsor of 461 studies on the registry; 78 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Zagazig University has 8 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 143 studies testing semaglutide in Obesity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI >30 will be randomized into three groups and followed for 6 months to assess changes in weight, BMI, lipid profile, and liver functions.
This is a single-center, randomized controlled trial planned at Al-Zafer Hospital, Najran, KSA.
150 non-diabetic obese participants (BMI >30, age >18) will be randomized into three equal groups: Group 1: Dulaglutide 1.5 mg weekly Group 2: Semaglutide 1.0 mg weekly Group 3: Tirzepatide 5 mg weekly, titrated as tolerated
Participants will be assessed at baseline, 3 months, and 6 months for weight, BMI, waist circumference, fasting glucose, lipid profile, and liver enzymes. Monthly follow-up will ensure medication adherence and monitor gastrointestinal adverse events.
Inclusion: BMI >30, age >18, non-diabetic. Exclusion: Diabetes, liver disease, renal dysfunction, pancreatic disease, thyroid disease, psychological disorders, pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Includes 50 non-diabetic obese participants receiving dulaglutide 1.5 mg subcutaneous once weekly for 24 weeks
Drug: Dulaglutide
Includes 50 non-diabetic obese participants receiving semaglutide 2.4 mg subcutaneous once weekly for 24 weeks
Drug: Semagludtide
Includes 50 non-diabetic obese participants receiving Tirzepatide 15 mg subcutaneous once weekly for 24 weeks
Drug: Tirzepatide
weight control drug dulaglutide 1.5 mg subcutaneous injection GLP-1 receptor agonist
Weight control drug semaglutide 2.4 mg subcutanous injection GLP-1 receptor agonist
Weight control drug tirzepatide 15 mg subcutanous injection GLP-1 receptor agonist
change in body weight at 3 and 6 months
Change from baseline in body weight (kg) at 3 and 6 months analyzed separately among obese non-diabetic participants receiving weekly GLP-1 receptor agonists.
Time frame: Baseline, Week 12 (3 months) and Week 24 (6 months)
Change in Body Mass Index (BMI)
Change in BMI from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: kg/m²
Time frame: Baseline, 3 months, and 6 months
Change in Glycated Hemoglobin (HbA1c)
Change in HbA1c from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: %
Time frame: Baseline, 3 months, and 6 months
Change in Low-Density Lipoprotein Cholesterol (LDL-C)
Change in LDL-C from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: mg/dL
Time frame: Baseline, 3 months, and 6 months
Change in Triglycerides
Change in serum triglyceride concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: mg/dL
Time frame: Baseline, 3 months, and 6 months
Change in High-Density Lipoprotein Cholesterol (HDL-C)
Change in HDL-C from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: mg/dL
Time frame: Baseline, 3 months, and 6 months
Change in Total Cholesterol (TC)
Change in TC from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: mg/dL
Time frame: Baseline, 3 months, and 6 months
Change in Alanine Aminotransferase (ALT)
Change in serum ALT concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: U/L
Time frame: Baseline, 3 months, and 6 months
Change in Aspartate Aminotransferase (AST)
Change in serum AST concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: U/L
Time frame: Baseline, 3 months, and 6 months]
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Ran from Nov 2025 to primary completion in Apr 2026, 4 months.
Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's 4 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dulaglutide · Semaglutide · Tirzepatide